0001592052-13-000003.txt : 20131203
0001592052-13-000003.hdr.sgml : 20131203
20131203113257
ACCESSION NUMBER: 0001592052-13-000003
CONFORMED SUBMISSION TYPE: D/A
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20131203
DATE AS OF CHANGE: 20131203
EFFECTIVENESS DATE: 20131203
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Centrexion Corp
CENTRAL INDEX KEY: 0001592052
IRS NUMBER: 320402377
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D/A
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-206864
FILM NUMBER: 131253627
BUSINESS ADDRESS:
STREET 1: 509 S. EXETER ST., SUITE 202
CITY: BALTIMORE
STATE: MD
ZIP: 21202
BUSINESS PHONE: 212-956-1111
MAIL ADDRESS:
STREET 1: 509 S. EXETER ST., SUITE 202
CITY: BALTIMORE
STATE: MD
ZIP: 21202
D/A
1
primary_doc.xml
X0707
D/A
LIVE
0001592052
Centrexion Corp
509 S. EXETER ST., SUITE 202
BALTIMORE
MD
MARYLAND
21202
212-956-1111
DELAWARE
None
None
Corporation
true
2013
Sol
Barer
c/o Centrexion Corporation
509 S. Exeter St., Suite 202
Baltimore
MD
MARYLAND
21202
Director
Isaac
Blech
c/o Centrexion Corporation
509 S. Exeter St., Suite 202
Baltimore
MD
MARYLAND
21202
Director
Kerrie
L.
Brady
c/o Centrexion Corporation
509 S. Exeter St., Suite 202
Baltimore
MD
MARYLAND
21202
Executive Officer
James
N.
Campbell
c/o Centrexion Corporation
509 S. Exeter St., Suite 202
Baltimore
MD
MARYLAND
21202
Executive Officer
Director
Jeffrey
B.
Kindler
c/o Centrexion Corporation
509 S. Exeter St., Suite 202
Baltimore
MD
MARYLAND
21202
Executive Officer
Arnold
L.
Oronsky
c/o Centrexion Corporation
509 S. Exeter St., Suite 202
Baltimore
MD
MARYLAND
21202
Director
Biotechnology
Decline to Disclose
- 06b
true
0001592052-13-000001
2013-11-20
false
true
true
Series B Convertible Preferred Stock
true
(1) 1,996,980 shares issued in connection with a merger;
(2) 418,950 shares issued in connection with the conversion of existing bridge notes of Issuer; and
(3) 142,857 shares issued as payment for consulting services.
0
N/A
None
Maxim Group LLC
120708
405 Lexington Avenue
New York
NY
NEW YORK
10174
All States
false
35000000
14728886
20271114
false
98
1178311
0
Maxim will also receive warrants to purchase 673,321 shares of Series B Convertible Preferred Stock of Centrexion Corporation, par value $0.001 per share as part of its fee for its placement agent services.
416388
true
To pay back salary for executive officers:
(1) Kerrie L. Brady,
(2) James N. Campbell and
(3) Jeffrey B. Kindler.
false
Centrexion Corp
/s/ Sol Barer
Sol Barer
Authorized Person
2013-12-03